Kano Y, Narita T, Suzuki K, Akutsu M, Suda K, Sakamoto S, Miura Y
Division of Medical Oncology, Tochigi Cancer Center, Japan.
Br J Cancer. 1992 Aug;66(2):281-6. doi: 10.1038/bjc.1992.257.
We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were incubated for 3 days in the presence of two drugs (ICRF-154 and one other), and cell growth inhibition was determined by MTT assay. Effects of drug combinations at the ID50 level were analysed using the isobologram method (Steel). In the lymphoblastic leukaemia cell lines, MOLT-3, HSB, and B-ALL, supra-additive effects were observed for ICRF-154 in combination with amsacrine, bleomycin, doxorubicin, and etoposide. Additive effects were observed for its combinations with cisplatin, CPT-11, cytosine arabinoside, 5-fluorouracil, mitomycin C, and vincristine. Sub-additive to protective effects were observed in combination with methotrexate. In an erythroleukaemia cell line, K-562, no drug showed supra-additive effects with ICRF-154, while sub-additive to protective effects were observed for ICRF-154 in combination with cisplatin and methotrexate. The other drugs showed additive effects with ICRF-154. These results indicate that the combined effects of ICRF-154 with other agents vary, depending on the cell line. Against lymphoid malignancies, ICRF-154 would be advantageous when administered simultaneously with many anticancer agents. Of such agents, amsacrine, bleomycin, doxorubicin, and etoposide are the most suitable, while methotrexate is least suitable for such combined treatment.
我们研究了ICRF-154与11种抗癌药物联合使用对四种人类白血病细胞系的影响。细胞在两种药物（ICRF-154和另一种药物）存在的情况下培养3天，通过MTT法测定细胞生长抑制情况。使用等效线图法（Steel法）分析ID50水平下药物组合的效果。在淋巴细胞白血病细胞系MOLT-3、HSB和B-ALL中，观察到ICRF-154与安吖啶、博来霉素、阿霉素和依托泊苷联合使用时有超相加作用。其与顺铂、CPT-11、阿糖胞苷、5-氟尿嘧啶、丝裂霉素C和长春新碱联合使用时观察到相加作用。与甲氨蝶呤联合使用时观察到次相加至保护作用。在红白血病细胞系K-562中，没有药物与ICRF-154显示出超相加作用，而ICRF-154与顺铂和甲氨蝶呤联合使用时观察到次相加至保护作用。其他药物与ICRF-154联合使用时显示出相加作用。这些结果表明，ICRF-154与其他药物的联合效果因细胞系而异。对于淋巴系统恶性肿瘤，ICRF-154与许多抗癌药物同时给药时可能具有优势。在这些药物中，安吖啶、博来霉素、阿霉素和依托泊苷最适合，而甲氨蝶呤最不适合这种联合治疗。
